Astrazeneca Plc's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Astrazeneca Plc's ROA in the fourth quarter of 2025?
Astrazeneca Plc achieved a return on average assets (ROA) of 11.09 % in its fourth quarter of 2025, this is above AZN's average return on assets of 4.41%.
Astrazeneca Plcs assets during the 12 months ending in the fourth quarter of 2025 are valued at $114 billion

ROA has improved compared to 7.74% in the third quarter of 2025, due to net income growth.

However, within the Healthcare sector 100 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 1081.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	-21.86 %	9.65 %	-21.81 %	9.65 %	0.32 %
Y / Y Net Income Change	45.33 %	-	26.97 %	-	18.12 %
Net Income (TTM) in million	12,681	9,489	9,489	8,969	8,969
Return On Assets (TTM)	11.09 %	7.74 %	7.91 %	7.02 %	7.16 %
AZN's Total Ranking	# 1081	#	#	#	# 1263
Total Assets (TTM) in million	116,829	114,074	112,422	114,074	149,514
Seq. Total Assets Change	2.42 %	1.47 %	-1.45 %	-23.7 %	43.72 %
Seq. Net Income Change	-	-	-	-	-

AZN's 5 Years Annual ROA >> Back to AZN Management Effectiveness >> Compare AZN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 42
Sector	# 101
Overall	# 799

Return On Assets Statistics
High	Average	Low
8.97 %	4.41 %	0.11 %
(Dec 31 2025)		(Dec 31 2021)

Financial Statements
Astrazeneca Plc's Assets	$ 116,829 million	AZN's Balance sheet
Astrazeneca Plc's Income	$ 10,233 million	Quarterly AZN's Income Statement
AZN's Income by Division		See AZN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	8.46 %	0.32 %	3.69 %	-6.6 %	68.21 %
Total Assets in million	162,157	149,514	149,041	143,733	153,886
Y / Y Net Income Change	45.33 %	18.12 %	81.02 %	2763.48 %	-96.34 %
Net Income in million	10,233	7,041	5,961	3,293	115
Annual Return On Assets	6.31 %	4.71 %	4 %	2.29 %	0.07 %

AZN's 5 Years Annual ROA >> Back to AZN Management Effectiveness >> Compare AZN ROA to its Competitors

Comment on AZN's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 6.31 % compared to prior year, due to annual net income growth of 45.33 % to $10,233.00 million, while value of Astrazeneca Plc's overall assets grew just by 8.46 % to $162,157.00 million, compared to $162,157.00 a year before.

More Return On Assets Ratios
AZN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AZN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AZN's Competitors
Subscribers only: Roa for Astrazeneca Plc's Suppliers
Subscribers only: Return On Assets for AZN's Customers

You may also want to know
AZN's Roi	AZN's Inventory Turnover Ratio	AZN's Growth Rates	AZN's Dividend Comparisons
	AZN's Profitability Ratios	AZN's Asset Turnover Ratio	AZN's Dividend Growth
AZN's Roe	AZN's Valuation Ratios	AZN's Financial Strength Ratios	AZN's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector	ROA
Acadia Pharmaceuticals Inc	29.77 %
Newgenivf Group Limited	29.73 %
Hutchmed china Limited	26.11 %
Petros Pharmaceuticals inc	26.04 %
Adma Biologics Inc	25.98 %
Theravance Biopharma inc	25.35 %
Ptc Therapeutics inc	25.21 %
Qhslab Inc	25.12 %
Medpace Holdings Inc	25.07 %
Mettler toledo International Inc	25.07 %
Compugen Ltd	22.57 %
Lifemd Inc	21.39 %
Catalyst Pharmaceuticals Inc	21.24 %
Iradimed Corporation	20.83 %
Incyte Corporation	20.70 %
Transmedics Group Inc	20.34 %
Eli Lilly And Company	19.76 %
Innoviva Inc	19.19 %
Novo Nordisk A	18.87 %
Resmed Inc	18.44 %
Pro dex Inc	18.07 %
Zoetis Inc	17.92 %
Inspire Medical Systems inc	17.91 %
United Therapeutics Corporation	17.29 %
Krystal Biotech Inc	17.12 %
Electromed Inc	16.83 %
Arrowhead Pharmaceuticals Inc	16.32 %
Vertex Pharmaceuticals Inc	16.23 %
Chemed Corporation	16.06 %
Mimedx Group Inc	15.89 %

Date modified: 2026-07-07T09:23:46+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.